Sign up
Pharma Capital

Sareum Holdings created drug to be showcased at leading cancer event next month

Sareum's partner Sierra Oncology has provided the essence of what it will share with delegates at the upcoming American Society of Clinical Oncology in Chicago
woman at microscope
Promising progress has been made, though the drug is at the early clinical phase

The findings from clinical trials of a cancer drug developed by Sareum Holdings PLC (LON:SAR) will be showcased at a leading international cancer conference next month.

SRA737 is one of a new breed of drugs called cell cycle checkpoint inhibitors. It is currently being developed by a Canadian firm called Sierra Oncology, which has carried out phase I/II trials on people with advanced forms of the disease.

An abstract from the data which is being shared at the American Society of Clinical Oncology (ASCO) in Chicago reveals the maximum dose for SRA737 used on its own as a monotherapy was 1,000mg a day, while the recommended phase II dose is 800mg.

It also said the phase II study will treat patients who are most likely genetically to benefit from checkpoint-1 inhibitors.

Well tolerated 

A second abstract reveals SRA737 is “well tolerated” when used in combination with chemotherapy. The first-in-human study also provided proof-of-concept that the chemo “effectively potentiates” (increases the power of) SRA737.

“This novel replication stress-targeted therapy warrants further evaluation in genetically pre-defined solid tumours,” the abstract adds.

Sierra Oncology chief executive, Dr Nick Glover, said: "The two studies have enrolled patients across a range of tumour indications including a variety of prospectively selected genetic contexts, allowing us to broadly survey the cancer landscape for activity signals in response to administration of SRA737 alone and in combination with non-cytotoxic low dose gemcitabine.

“These preliminary data have also enabled us to correlate clinical findings with tumour origin and genetic signature, ascertain whether the exogenous induction of replication stress via low dose gemcitabine can enhance SRA737's activity, and determine potential next steps in the development path for SRA737."

The ASCO event runs from May 31 to June 4. The information will go on display via a poster on June 1. For more details click here.

Separately, Sierra Oncology will be hosting an analyst and investor event from 6:00-7:00am on June 3 in Chicago to discuss these clinical findings and “potential next steps in the development strategy for SRA737”.

Sareum shares rose 8.5% to 0.7p.

 --- Adds share price ---

Ian_55ae0ddd437b7.jpg
Why Invest In Sareum Holdings PLC? Read More Here

Register here to be notified of future SAR Company articles
View full SAR profile View Profile
Article

Sareum Holdings primed for progress

View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.